Skip to main content
. Author manuscript; available in PMC: 2014 Jan 29.
Published in final edited form as: Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358

Fig. 5.

Fig. 5

Pazopanib and paclitaxel combine to affect cell fate in KTC2 ATC cells. (A) Images (captured from real-time video microscopy) showing morphological effects of single-agent and combined pazopanib (Paz) and paclitaxel (Tax) relative to diluent control. (B) Summary data indicating effects of single-agent and combined pazopanib and paclitaxel relative to diluent control on KTC2 cell fate after 48-hour exposures across three replicate experiments. Left panel, morphologically normal cells; middle panel, multinucleated cells; right panel, cells dying after dysfunctional mitosis [all expressed as % total time = 0 cells; data shown in (A) are representative of three independent experiments]. Error bars in (B) represent 1 sample SD, triplicate experiments; NS, not statistically significant; significance levels shown for one-sided t tests.